somatische SV's zouden, na validatie, kunnen worden gebruikt als patiënt-specifieke bio-:@0.147059:0.121273:0.882353:0.121273:0.882353:0.100900:0.147059:0.100900:0.007875:0.010843:0.017577:0.008811:0.006437:0.005615:0.007875:0.008765:0.011299:0.009039:0.003276:0.010112:0.015089:0.003196:0.007670:0.003276:0.008834:0.010820:0.011345:0.011322:0.009039:0.011756:0.004497:0.003276:0.011687:0.009291:0.003276:0.009838:0.009405:0.005250:0.005545:0.011573:0.008811:0.006437:0.005547:0.008743:0.004497:0.003276:0.010274:0.011413:0.011756:0.011596:0.009039:0.011756:0.003273:0.014518:0.010845:0.007442:0.011322:0.009039:0.011756:0.003276:0.009656:0.008902:0.010820:0.007964:0.011413:0.005752:0.010274:0.006437:0.003273:0.009405:0.005250:0.007670:0.003276:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005613:0.008948:0.010274:0.009039:0.003276:0.010820:0.005547:0.011048:0.007533
markers voor het volgen van kanker in circulerend tumor-DNA (ctDNA) door middel :@0.147059:0.141852:0.886466:0.141852:0.886466:0.121479:0.147059:0.121479:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.005182:0.009633:0.011276:0.010843:0.007807:0.005182:0.011299:0.009131:0.006437:0.005182:0.009633:0.010934:0.005250:0.009656:0.009039:0.011756:0.005182:0.009838:0.009085:0.011756:0.005182:0.010614:0.009085:0.011870:0.010274:0.009039:0.007807:0.005182:0.005615:0.011756:0.005182:0.008994:0.005615:0.007442:0.009108:0.011550:0.005182:0.009039:0.007442:0.009039:0.011596:0.011391:0.005182:0.006163:0.011413:0.017485:0.010843:0.007236:0.007533:0.015773:0.015408:0.014929:0.005182:0.006939:0.009108:0.006437:0.015773:0.015408:0.014929:0.006939:0.005182:0.011322:0.011276:0.010843:0.007807:0.005182:0.017645:0.005547:0.011322:0.011322:0.008948:0.005250:0.004109
van ultragevoelige PCR-methoden. We hebben onze assay toegepast op tien ovarium- :@0.147059:0.162431:0.886389:0.162431:0.886389:0.142058:0.147059:0.142058:0.009838:0.009085:0.011756:0.005798:0.011550:0.004908:0.006437:0.007898:0.009199:0.009656:0.009336:0.009633:0.011276:0.008948:0.005250:0.005615:0.009656:0.009039:0.005798:0.012167:0.014678:0.012349:0.007533:0.017483:0.009131:0.006620:0.011299:0.011276:0.011322:0.009039:0.011756:0.004497:0.005798:0.018649:0.009039:0.005798:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.005798:0.010843:0.011756:0.008834:0.009039:0.005798:0.009291:0.007533:0.007944:0.008925:0.009724:0.005798:0.006209:0.011276:0.009039:0.009656:0.009131:0.011368:0.009291:0.007510:0.006437:0.005798:0.010820:0.011276:0.005798:0.006437:0.005545:0.009039:0.011756:0.005798:0.010866:0.009838:0.009085:0.007807:0.005271:0.011413:0.017645:0.007533:0.004109
en prostaatkankermonsters en hebben in slechts enkele dagen meerdere biomarkers per :@0.147059:0.183009:0.886532:0.183009:0.886532:0.162636:0.147059:0.162636:0.009039:0.011756:0.004246:0.011071:0.007442:0.010957:0.007510:0.006551:0.009382:0.008811:0.006620:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.017485:0.010843:0.011619:0.007510:0.006209:0.009039:0.007624:0.007670:0.004246:0.009039:0.011756:0.004246:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.004246:0.005615:0.011756:0.004246:0.007556:0.005182:0.009108:0.008763:0.011096:0.006437:0.007670:0.004246:0.009039:0.011868:0.010272:0.008950:0.005182:0.009039:0.004246:0.011573:0.009199:0.009656:0.009039:0.011756:0.004246:0.017485:0.009108:0.009039:0.007442:0.011322:0.009039:0.007442:0.009039:0.004246:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004246:0.011505:0.009039:0.007807:0.004109
monster verkregen. We hebben in retrospect aangetoond dat longitudinale monitoring :@0.147059:0.203588:0.886487:0.203588:0.886487:0.183215:0.147059:0.183215:0.017485:0.010843:0.011619:0.007510:0.006209:0.009039:0.007807:0.005182:0.009633:0.009039:0.007601:0.010706:0.007442:0.009039:0.009656:0.009039:0.011756:0.004497:0.005182:0.018649:0.009039:0.005182:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.005182:0.005615:0.011756:0.005182:0.007442:0.009131:0.006437:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005182:0.009384:0.009085:0.011459:0.009656:0.009131:0.006209:0.011276:0.010843:0.011596:0.011391:0.005182:0.011573:0.008809:0.006437:0.005182:0.005182:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005182:0.009039:0.005182:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.004109
van de kankerdynamiek mogelijk was met behulp van deze somatische SV-biomarkers. :@0.147059:0.224167:0.886418:0.224167:0.886418:0.203794:0.147059:0.203794:0.009838:0.009085:0.011756:0.004931:0.011322:0.009039:0.004931:0.010614:0.009085:0.011870:0.010272:0.009039:0.007442:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008948:0.010523:0.004931:0.017485:0.011048:0.009656:0.008948:0.005250:0.005273:0.005273:0.010523:0.004931:0.014723:0.009291:0.007670:0.004931:0.017485:0.009131:0.006437:0.004931:0.011254:0.008948:0.011094:0.011550:0.004908:0.011276:0.004931:0.009838:0.009085:0.011756:0.004931:0.011322:0.009336:0.008834:0.009039:0.004931:0.007875:0.010843:0.017577:0.008811:0.006437:0.005615:0.007875:0.008765:0.011299:0.009039:0.004931:0.010112:0.013308:0.007533:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004497:0.004109
Samenvattend maakte onze methode een snelle en kosteneffectieve identificatie mogelijk :@0.147059:0.244745:0.886535:0.244745:0.886535:0.224373:0.147059:0.224373:0.010112:0.009085:0.017485:0.009039:0.011368:0.009838:0.008811:0.006163:0.006209:0.009039:0.011596:0.011391:0.003401:0.017577:0.009382:0.009405:0.010272:0.006209:0.009039:0.003401:0.010843:0.011756:0.008834:0.009039:0.003401:0.017485:0.009131:0.006620:0.011299:0.011276:0.011322:0.009039:0.003401:0.009108:0.009039:0.011756:0.003401:0.007601:0.011598:0.008948:0.005385:0.005184:0.009039:0.003401:0.009039:0.011756:0.003401:0.010272:0.010957:0.007510:0.006209:0.009039:0.011596:0.009039:0.005969:0.005787:0.009108:0.009108:0.006437:0.005547:0.009336:0.009633:0.009039:0.003401:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.009039:0.003401:0.017485:0.011048:0.009656:0.008948:0.005250:0.005273:0.005273:0.010523:0.004109
van een reeks patiëntspecifieke SV's die kunnen worden gebruikt om ctDNA-dynamiek :@0.147059:0.265324:0.886462:0.265324:0.886462:0.244951:0.147059:0.244951:0.009838:0.009085:0.011756:0.004485:0.009108:0.009039:0.011756:0.004485:0.007442:0.009108:0.008948:0.010523:0.007670:0.004485:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005613:0.008948:0.010272:0.009039:0.004485:0.010112:0.015089:0.003196:0.007670:0.004485:0.011391:0.005547:0.009039:0.004485:0.010272:0.011413:0.011756:0.011596:0.009039:0.011756:0.004485:0.014518:0.010843:0.007442:0.011324:0.009039:0.011756:0.004483:0.009658:0.008900:0.010820:0.007967:0.011413:0.005752:0.010272:0.006437:0.004485:0.010843:0.017645:0.004485:0.009108:0.006437:0.015773:0.015408:0.013605:0.007533:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008948:0.010523:0.004109
te bestuderen.:@0.147059:0.285903:0.264822:0.285903:0.264822:0.265530:0.147059:0.265530:0.006209:0.009039:0.004109:0.011254:0.009039:0.007510:0.006163:0.011345:0.011322:0.009039:0.007442:0.009039:0.011756:0.004497
We hebben ook een assay ontwikkeld die gebruik maakt van op CRISPR-Cas9 geba-:@0.147059:0.327060:0.882353:0.327060:0.882353:0.306687:0.147059:0.306687:0.018649:0.009039:0.006688:0.011302:0.008902:0.010932:0.011254:0.009039:0.011756:0.006688:0.011276:0.010934:0.010523:0.006688:0.009108:0.009039:0.011756:0.006688:0.009291:0.007533:0.007944:0.008925:0.009724:0.006688:0.010843:0.011391:0.006437:0.014723:0.005752:0.010888:0.010272:0.008948:0.005182:0.011391:0.006688:0.011391:0.005547:0.009039:0.006688:0.009656:0.008902:0.010820:0.007967:0.011413:0.005752:0.010523:0.006688:0.017577:0.009382:0.009405:0.010272:0.006437:0.006688:0.009838:0.009087:0.011756:0.006688:0.010820:0.011276:0.006688:0.014678:0.013376:0.007259:0.009770:0.011664:0.012349:0.007533:0.014974:0.009291:0.007670:0.010432:0.006688:0.009656:0.008902:0.011117:0.009217:0.007533
seerde verrijking van genomische targets bij pediatrische leukemieën uit de lymfoïde lijn. :@0.147059:0.347639:0.886526:0.347639:0.886526:0.327266:0.147059:0.327266:0.007875:0.009108:0.009039:0.007442:0.011322:0.009039:0.003356:0.009633:0.009039:0.007807:0.007807:0.005273:0.005273:0.010706:0.005615:0.011459:0.009861:0.003356:0.009838:0.009085:0.011756:0.003356:0.009656:0.009039:0.011596:0.010843:0.017645:0.005615:0.007875:0.008765:0.011299:0.009039:0.003356:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.003356:0.010818:0.005273:0.005273:0.003356:0.011505:0.009108:0.011391:0.005796:0.008811:0.006437:0.007807:0.005615:0.007875:0.008765:0.011299:0.009039:0.003356:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.009108:0.009039:0.011756:0.003356:0.011413:0.005271:0.006437:0.003356:0.011322:0.009039:0.003356:0.005184:0.009724:0.017645:0.006026:0.010843:0.005547:0.011322:0.009039:0.003356:0.005250:0.005271:0.005273:0.011756:0.004497:0.004109
In :@0.147059:0.368218:0.169817:0.368218:0.169817:0.347845:0.147059:0.347845:0.006894:0.011756:0.004109
hoofdstuk 6:@0.170908:0.368218:0.278078:0.368218:0.278078:0.347085:0.170908:0.347085:0.011779:0.011756:0.011322:0.006391:0.011801:0.008035:0.006825:0.012096:0.011162:0.005090:0.010911
 hebben we ons gericht op loci die herhaaldelijk betrokken zijn bij gen-:@0.278073:0.368218:0.882353:0.368218:0.882353:0.347845:0.278073:0.347845:0.005205:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.005205:0.014518:0.009039:0.005205:0.010843:0.011619:0.007670:0.005205:0.009656:0.009039:0.007807:0.005547:0.008763:0.011096:0.006437:0.005205:0.010820:0.011276:0.005205:0.005182:0.011276:0.008994:0.005615:0.005205:0.011391:0.005547:0.009039:0.005205:0.011299:0.009039:0.007601:0.011391:0.009382:0.009405:0.005182:0.011322:0.008948:0.005250:0.005273:0.005273:0.010523:0.005205:0.011251:0.009131:0.006437:0.007442:0.010934:0.010888:0.010272:0.009039:0.011756:0.005205:0.008834:0.005273:0.005273:0.011756:0.005205:0.010820:0.005273:0.005273:0.005205:0.009656:0.009039:0.011699:0.007533
omische herschikkingen bij deze leukemieën, zoals de immunoglobuline (Ig) en T-cel-:@0.147059:0.388796:0.882353:0.388796:0.882353:0.368423:0.147059:0.368423:0.010843:0.017645:0.005615:0.007875:0.008765:0.011299:0.009039:0.005227:0.011299:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.010888:0.010706:0.005615:0.011459:0.009656:0.009039:0.011756:0.005227:0.010820:0.005273:0.005273:0.005227:0.011322:0.009336:0.008834:0.009039:0.005227:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.009108:0.009039:0.011756:0.004497:0.005227:0.008834:0.011139:0.009405:0.005250:0.007670:0.005227:0.011322:0.009039:0.005227:0.005615:0.017645:0.017280:0.011413:0.011596:0.011048:0.009930:0.005182:0.010957:0.010797:0.011548:0.005250:0.005615:0.011596:0.009039:0.005227:0.006939:0.006483:0.009861:0.006939:0.005227:0.009039:0.011756:0.005227:0.011801:0.007533:0.008994:0.008948:0.005341:0.007533
receptor (TCR) loci, en de KMT2A en SIL-TAL1 fusiegenen loci. Deze loci worden veel :@0.147059:0.409375:0.886464:0.409375:0.886464:0.389002:0.147059:0.389002:0.007442:0.009108:0.008994:0.009131:0.011048:0.006209:0.010843:0.007807:0.004337:0.006825:0.013057:0.014678:0.013376:0.006939:0.004337:0.005182:0.011276:0.008994:0.005341:0.004497:0.004337:0.009039:0.011756:0.004337:0.011322:0.009039:0.004337:0.014541:0.019608:0.013354:0.010432:0.014929:0.004337:0.009039:0.011756:0.004337:0.009770:0.007259:0.011391:0.007533:0.011710:0.014929:0.011619:0.010432:0.004337:0.006366:0.011413:0.007601:0.005547:0.009039:0.009656:0.009039:0.011598:0.009039:0.011756:0.004337:0.005182:0.011276:0.008994:0.005341:0.004497:0.004337:0.016228:0.009336:0.008834:0.009039:0.004337:0.005182:0.011276:0.008994:0.005615:0.004337:0.014518:0.010843:0.007442:0.011324:0.009039:0.011756:0.004337:0.009633:0.009108:0.008948:0.005250:0.004109
gebruikt voor op PCR gebaseerde tracering van minimale restziekte op basis van de pa-:@0.147059:0.429954:0.882353:0.429954:0.882353:0.409581:0.147059:0.409581:0.009656:0.008902:0.010820:0.007967:0.011413:0.005752:0.010272:0.006437:0.004497:0.009633:0.011276:0.010843:0.007807:0.004497:0.010820:0.011276:0.004497:0.012167:0.014678:0.013376:0.004497:0.009656:0.008902:0.011117:0.009291:0.007875:0.009108:0.009039:0.007442:0.011322:0.009039:0.004497:0.006437:0.007898:0.009291:0.008994:0.009039:0.007807:0.005615:0.011459:0.009861:0.004497:0.009838:0.009085:0.011756:0.004497:0.017645:0.005615:0.011756:0.005615:0.017574:0.009405:0.005182:0.009039:0.004497:0.007442:0.009039:0.007510:0.006506:0.008834:0.005545:0.008950:0.010272:0.006209:0.009039:0.004497:0.010820:0.011276:0.004497:0.011117:0.009291:0.007601:0.005615:0.007670:0.004497:0.009838:0.009087:0.011756:0.004497:0.011322:0.009039:0.004497:0.011368:0.009357:0.007533
tiëntspecifieke herschikkingen. We hebben onze assay toegepast op tien acute lymfoïde :@0.147059:0.450532:0.886416:0.450532:0.886416:0.430160:0.147059:0.430160:0.006437:0.005547:0.009039:0.011391:0.006437:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008948:0.010272:0.009039:0.004908:0.011299:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.010886:0.010706:0.005615:0.011459:0.009656:0.009039:0.011756:0.004497:0.004908:0.018649:0.009039:0.004908:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.004908:0.010843:0.011756:0.008834:0.009039:0.004908:0.009291:0.007533:0.007944:0.008925:0.009724:0.004908:0.006209:0.011276:0.009039:0.009656:0.009131:0.011368:0.009291:0.007510:0.006437:0.004908:0.010820:0.011276:0.004908:0.006437:0.005547:0.009039:0.011756:0.004908:0.009291:0.009106:0.011073:0.006209:0.009039:0.004908:0.005184:0.009724:0.017645:0.006024:0.010843:0.005547:0.011322:0.009039:0.004109
leukemie monsters en hebben aangetoond dat we met succes de fusie, Ig en TCR loci :@0.147059:0.471111:0.886423:0.471111:0.886423:0.450738:0.147059:0.450738:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005547:0.009039:0.006072:0.017485:0.010843:0.011619:0.007512:0.006209:0.009039:0.007624:0.007670:0.006072:0.009039:0.011756:0.006072:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.006072:0.009384:0.009085:0.011459:0.009656:0.009131:0.006209:0.011276:0.010843:0.011596:0.011391:0.006072:0.011573:0.008811:0.006437:0.006072:0.014518:0.009039:0.006072:0.017485:0.009131:0.006437:0.006072:0.007510:0.011345:0.008994:0.008994:0.009039:0.007670:0.006072:0.011322:0.009039:0.006072:0.006369:0.011413:0.007601:0.005547:0.008743:0.004497:0.006072:0.006483:0.009861:0.006072:0.009039:0.011756:0.006072:0.013057:0.014678:0.013376:0.006072:0.005182:0.011276:0.008994:0.005615:0.004109
hebben verrijkt. We hebben met succes bekende doelen van minimale restziekte bij deze :@0.147059:0.491690:0.886555:0.491690:0.886555:0.471317:0.147059:0.471317:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.003995:0.009635:0.009039:0.007807:0.007807:0.005271:0.005273:0.010272:0.006437:0.004497:0.003995:0.018649:0.009039:0.003995:0.011299:0.008902:0.010934:0.011251:0.009039:0.011756:0.003995:0.017485:0.009131:0.006437:0.003995:0.007510:0.011345:0.008994:0.008994:0.009039:0.007670:0.003995:0.011254:0.008948:0.010272:0.009039:0.011596:0.011322:0.009039:0.003995:0.011324:0.011274:0.008948:0.005182:0.009039:0.011756:0.003995:0.009838:0.009085:0.011756:0.003995:0.017645:0.005615:0.011756:0.005615:0.017577:0.009405:0.005182:0.009039:0.003995:0.007442:0.009039:0.007512:0.006503:0.008834:0.005547:0.008948:0.010272:0.006211:0.009039:0.003995:0.010820:0.005273:0.005273:0.003995:0.011322:0.009336:0.008834:0.009039:0.004109
patiënten gevalideerd binnen twee dagen na ontvangst van het monster en we hebben :@0.147059:0.512269:0.886514:0.512269:0.886514:0.491896:0.147059:0.491896:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006209:0.009039:0.011756:0.005684:0.009656:0.009336:0.009838:0.009405:0.005250:0.005547:0.011322:0.009108:0.009039:0.007442:0.011391:0.005684:0.010820:0.005615:0.011756:0.011596:0.009039:0.011756:0.005684:0.006437:0.014518:0.009108:0.009039:0.005684:0.011573:0.009199:0.009656:0.009039:0.011756:0.005684:0.011690:0.009291:0.005684:0.010843:0.011391:0.006437:0.009838:0.009085:0.011459:0.009724:0.007510:0.006437:0.005684:0.009838:0.009087:0.011756:0.005684:0.011299:0.009131:0.006437:0.005684:0.017485:0.010843:0.011619:0.007510:0.006209:0.009039:0.007807:0.005684:0.009039:0.011756:0.005684:0.014518:0.009039:0.005684:0.011299:0.008902:0.010934:0.011254:0.009039:0.011756:0.004109
een aanvullende reeks patiëntspecifieke herschikkingen geïdentificeerd. Onze aanpak :@0.147059:0.532847:0.886441:0.532847:0.886441:0.512474:0.147059:0.512474:0.009108:0.009039:0.011756:0.007145:0.009382:0.009085:0.011368:0.009838:0.011550:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.007145:0.007442:0.009108:0.008948:0.010523:0.007670:0.007145:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008948:0.010272:0.009039:0.007145:0.011302:0.009039:0.007624:0.007873:0.008765:0.011459:0.005752:0.010888:0.010706:0.005615:0.011459:0.009656:0.009039:0.011756:0.007145:0.009656:0.009039:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.008994:0.009108:0.009039:0.007442:0.011117:0.004497:0.007145:0.016298:0.011756:0.008834:0.009039:0.007145:0.009382:0.009085:0.011391:0.011368:0.009405:0.010523:0.004109
vormt een geschikt alternatief voor de huidige meerstaps biomarker-identificatie assays :@0.147059:0.553426:0.886482:0.553426:0.886482:0.533053:0.147059:0.533053:0.009633:0.010843:0.007807:0.017280:0.006437:0.004908:0.009108:0.009039:0.011756:0.004908:0.009656:0.009039:0.007873:0.008768:0.011459:0.005750:0.010272:0.006437:0.004908:0.009405:0.004908:0.006209:0.009039:0.007807:0.011687:0.008811:0.006437:0.005547:0.009039:0.006209:0.004908:0.009633:0.011276:0.010843:0.007807:0.004908:0.011322:0.009039:0.004908:0.011094:0.011413:0.005547:0.011391:0.005615:0.009653:0.009039:0.004908:0.017485:0.009108:0.009039:0.007624:0.007510:0.006551:0.008811:0.011185:0.007670:0.004908:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007236:0.007533:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.009039:0.004908:0.009291:0.007533:0.007941:0.008928:0.009724:0.007670:0.004109
bij lymfoïde leukemie, met verhoogde snelheid en detectiegevoeligheid.:@0.147059:0.574005:0.745735:0.574005:0.745735:0.553632:0.147059:0.553632:0.010820:0.005273:0.005273:0.004109:0.005182:0.009724:0.017645:0.006026:0.010843:0.005547:0.011322:0.009039:0.004109:0.005182:0.009128:0.011550:0.010274:0.009039:0.017645:0.005545:0.008743:0.004497:0.004109:0.017485:0.009131:0.006437:0.004109:0.009633:0.009039:0.007601:0.011302:0.011274:0.011048:0.009656:0.011322:0.009039:0.004109:0.007601:0.011598:0.008946:0.005387:0.011302:0.009039:0.005545:0.011391:0.004109:0.009039:0.011756:0.004109:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.009039:0.009656:0.009336:0.009633:0.011276:0.008948:0.005250:0.005615:0.009930:0.011299:0.009039:0.005547:0.011117:0.004497
Ten slotte heb ik in :@0.147059:0.615162:0.311754:0.615162:0.311754:0.594789:0.147059:0.594789:0.010866:0.009039:0.011756:0.004771:0.007556:0.005182:0.010820:0.006163:0.006209:0.009039:0.004771:0.011299:0.008902:0.011025:0.004771:0.005752:0.010523:0.004771:0.005615:0.011756:0.004109
hoofdstuk 7:@0.312462:0.615162:0.419221:0.615162:0.419221:0.594029:0.312462:0.594029:0.011779:0.011756:0.011322:0.006391:0.011801:0.008035:0.006825:0.012096:0.011162:0.004679:0.010911
 de technologische vooruitgang die in de vorige hoofd-:@0.419216:0.615162:0.882353:0.615162:0.882353:0.594789:0.419216:0.594789:0.004771:0.011322:0.009039:0.004771:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005615:0.007875:0.008765:0.011299:0.009039:0.004771:0.009633:0.011276:0.010843:0.007967:0.011413:0.005273:0.006437:0.009861:0.009085:0.011459:0.009861:0.004771:0.011391:0.005547:0.009039:0.004771:0.005615:0.011756:0.004771:0.011322:0.009039:0.004771:0.009635:0.010843:0.007807:0.005615:0.009656:0.009039:0.004771:0.011299:0.011276:0.010843:0.006026:0.011461:0.007533
stukken zijn gepresenteerd bediscussieerd. Ik heb de voordelen van PDO-technologie :@0.147059:0.635741:0.886507:0.635741:0.886507:0.615368:0.147059:0.615368:0.007510:0.006163:0.011550:0.010888:0.010272:0.009039:0.011756:0.006140:0.008834:0.005273:0.005273:0.011756:0.006140:0.009656:0.009131:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009108:0.009039:0.007442:0.011391:0.006140:0.011254:0.009108:0.011391:0.005615:0.007873:0.009108:0.011413:0.007533:0.007601:0.005547:0.009108:0.009039:0.007442:0.011117:0.004497:0.006140:0.007190:0.010523:0.006140:0.011299:0.008902:0.011025:0.006140:0.011322:0.009039:0.006140:0.009633:0.011276:0.010843:0.007442:0.011322:0.008948:0.005182:0.009039:0.011756:0.006140:0.009838:0.009085:0.011756:0.006140:0.011664:0.016504:0.016412:0.007533:0.006209:0.009106:0.008768:0.011459:0.011598:0.010934:0.005182:0.011048:0.009861:0.005545:0.009039:0.004109
voor eierstokkankeronderzoek uitgelegd, maar ook de uitdagingen voor de verdere im-:@0.147059:0.656319:0.882353:0.656319:0.882353:0.635947:0.147059:0.635947:0.009633:0.011276:0.010843:0.007807:0.004748:0.009039:0.005547:0.009039:0.007624:0.007510:0.006209:0.010934:0.010888:0.010614:0.009085:0.011870:0.010272:0.009039:0.007442:0.010843:0.011596:0.011322:0.009039:0.007807:0.008834:0.011276:0.008948:0.010523:0.004748:0.011413:0.005273:0.006437:0.009656:0.008948:0.005182:0.009039:0.009656:0.011117:0.004497:0.004748:0.017577:0.009382:0.009085:0.007807:0.004748:0.011274:0.010936:0.010523:0.004748:0.011320:0.009039:0.004748:0.011413:0.005273:0.006209:0.011573:0.009199:0.009861:0.005615:0.011459:0.009656:0.009039:0.011756:0.004748:0.009633:0.011276:0.010843:0.007807:0.004748:0.011322:0.009039:0.004748:0.009633:0.009039:0.007442:0.011322:0.009039:0.007442:0.009039:0.004748:0.005615:0.017714:0.007533
plementatie in de klinische zorg. Daarnaast besprak ik de bestaande uitdagingen om-:@0.147059:0.676898:0.882353:0.676898:0.882353:0.656525:0.147059:0.656525:0.011162:0.005182:0.009039:0.017485:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.009039:0.006209:0.005615:0.011756:0.006209:0.011322:0.009039:0.006209:0.010888:0.005250:0.005615:0.011756:0.005615:0.007873:0.008765:0.011299:0.009039:0.006209:0.008834:0.010843:0.007624:0.009679:0.004497:0.006209:0.016207:0.009382:0.009085:0.007807:0.011687:0.009382:0.009291:0.007510:0.006437:0.006209:0.011254:0.009039:0.007510:0.011071:0.007898:0.009405:0.010523:0.006209:0.005752:0.010523:0.006209:0.011322:0.009039:0.006209:0.011254:0.009039:0.007510:0.006551:0.009380:0.009085:0.011598:0.011322:0.009039:0.006209:0.011413:0.005273:0.006209:0.011573:0.009199:0.009861:0.005615:0.011459:0.009658:0.009039:0.011756:0.006209:0.010840:0.017668:0.007533
trent somatische SV’s en stel ik verschillende oplossingen voor om de kennis van de rol :@0.147059:0.697477:0.886507:0.697477:0.886507:0.677104:0.147059:0.677104:0.006437:0.007442:0.009039:0.011391:0.006437:0.004953:0.007873:0.010843:0.017577:0.008811:0.006437:0.005615:0.007875:0.008765:0.011299:0.009039:0.004953:0.010112:0.014929:0.001735:0.007670:0.004953:0.009039:0.011756:0.004953:0.007510:0.006209:0.008948:0.005250:0.004953:0.005752:0.010523:0.004953:0.009633:0.009039:0.007624:0.007873:0.008768:0.011459:0.005750:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.004953:0.010820:0.011162:0.005182:0.010957:0.007533:0.007601:0.005615:0.011459:0.009656:0.009039:0.011756:0.004953:0.009635:0.011274:0.010845:0.007807:0.004953:0.010843:0.017645:0.004953:0.011322:0.009039:0.004953:0.010272:0.009039:0.011756:0.011756:0.005615:0.007670:0.004953:0.009838:0.009085:0.011756:0.004953:0.011322:0.009039:0.004953:0.007442:0.010934:0.005250:0.004109
van somatische SV's bij kanker en implementatie van Nanopore sequencing technologie :@0.147059:0.718056:0.886553:0.718056:0.886553:0.697683:0.147059:0.697683:0.009838:0.009085:0.011756:0.004018:0.007875:0.010843:0.017577:0.008811:0.006437:0.005615:0.007875:0.008765:0.011299:0.009039:0.004018:0.010112:0.015089:0.003196:0.007670:0.004018:0.010820:0.005271:0.005273:0.004018:0.010614:0.009085:0.011870:0.010272:0.009039:0.007807:0.004018:0.009039:0.011756:0.004018:0.005615:0.017280:0.011162:0.005182:0.009039:0.017485:0.009039:0.011391:0.006551:0.008811:0.006437:0.005547:0.009039:0.004018:0.009838:0.009085:0.011756:0.004018:0.015545:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.004018:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004018:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009039:0.004109
te vergroten. Concluderend stelt dit proefschrift verschillende kanker genomics geba-:@0.147059:0.738634:0.882353:0.738634:0.882353:0.718261:0.147059:0.718261:0.006209:0.009039:0.006446:0.009635:0.009039:0.007624:0.009861:0.007442:0.010818:0.006211:0.009039:0.011756:0.004497:0.006446:0.014997:0.010843:0.011596:0.008765:0.004908:0.011345:0.011322:0.009039:0.007442:0.009039:0.011596:0.011391:0.006446:0.007512:0.006209:0.008946:0.004910:0.006437:0.006446:0.011391:0.005273:0.006437:0.006446:0.011071:0.007442:0.011276:0.009039:0.006072:0.007875:0.008765:0.011459:0.007807:0.005615:0.006197:0.006197:0.006446:0.009633:0.009039:0.007624:0.007875:0.008765:0.011459:0.005752:0.005387:0.005182:0.009039:0.011596:0.011322:0.009039:0.006446:0.010614:0.009087:0.011868:0.010272:0.009039:0.007807:0.006449:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.007670:0.006446:0.009656:0.008902:0.011117:0.009291:0.007533
seerde technologische mogelijkheden voor om kankeronderzoek vooruit te helpen en :@0.147059:0.759213:0.886462:0.759213:0.886462:0.738840:0.147059:0.738840:0.007875:0.009108:0.009039:0.007442:0.011322:0.009039:0.006163:0.006209:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005615:0.007873:0.008768:0.011299:0.009039:0.006163:0.017485:0.011048:0.009656:0.008948:0.005250:0.005273:0.005273:0.010886:0.011299:0.009108:0.011322:0.009039:0.011756:0.006163:0.009633:0.011276:0.010843:0.007807:0.006163:0.010843:0.017645:0.006163:0.010614:0.009087:0.011868:0.010272:0.009039:0.007442:0.010845:0.011596:0.011322:0.009039:0.007807:0.008834:0.011274:0.008948:0.010523:0.006163:0.009635:0.011274:0.010845:0.007964:0.011413:0.005273:0.006437:0.006163:0.006209:0.009039:0.006163:0.011299:0.008948:0.004908:0.011505:0.009039:0.011756:0.006163:0.009039:0.011756:0.004109
gepersonaliseerde diagnostische assays te ontwikkelen om het ziektebeloop van patiënt-:@0.147059:0.779792:0.882353:0.779792:0.882353:0.759419:0.147059:0.759419:0.009656:0.009131:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.007873:0.009108:0.009039:0.007442:0.011322:0.009039:0.004097:0.011391:0.005798:0.009197:0.009861:0.011598:0.010957:0.007510:0.006437:0.005615:0.007873:0.008765:0.011299:0.009039:0.004097:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004095:0.006209:0.009039:0.004097:0.010843:0.011391:0.006437:0.014723:0.005752:0.010888:0.010272:0.008948:0.005182:0.009039:0.011756:0.004095:0.010843:0.017645:0.004097:0.011299:0.009131:0.006437:0.004095:0.008834:0.005547:0.008948:0.010272:0.006209:0.008902:0.011254:0.008948:0.005182:0.011276:0.010820:0.011276:0.004095:0.009838:0.009087:0.011756:0.004095:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533
en positief te beïnvloeden.:@0.147059:0.800370:0.367358:0.800370:0.367358:0.779998:0.147059:0.779998:0.009039:0.011756:0.004109:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009039:0.006209:0.004109:0.006207:0.009039:0.004109:0.011254:0.009039:0.005615:0.011368:0.009907:0.005182:0.011276:0.009108:0.011322:0.009039:0.011756:0.004497
213:@0.890196:0.957873:0.914035:0.957873:0.914035:0.938882:0.890196:0.938882:0.007923:0.007325:0.008591
SAMENVATTING:@0.772374:0.066557:0.882354:0.066557:0.882354:0.045634:0.772374:0.045634:0.009405:0.009679:0.013582:0.008537:0.010706:0.008514:0.008674:0.007807:0.007807:0.004291:0.010706:0.010272